




FIG. 1

1/17



Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146




Figure 2

CVT-3146 and Coronary Flow Velocity Duration of Effect:

Dose (n)	Duration \geq 2.5 Baseline
10 μ g (4)	0
30 μ g (4)	0
100 μ g (3)	0.2 ± 0.2 minutes
300 μ g (4)	2.2 ± 1.3 minutes
400 μ g (8)	2.8 ± 0.8 minutes
500 μ g (4)	2.9 ± 1.3 minutes

3/17

Figure 3

Time Course of APV Ratio
(CVT-3146 400 µg)




Figure 4

5/17

Time Course of Heart Rate (CVT-3146 400 µg)




Figure 5

6/17




Figure 6


All Drug-Related Adverse Events Were Mild and Transient

Adverse Event	All Doses (n = 36)	400 µg (n = 9)
chest discomfort	3	3
increased heart rate	3	1
hypotension	2	2
flushing	2	1
shortness of breath	2	0
funny taste in mouth	1	0
sensation in mouth, sinus, and chest	1	0
headache	1	0
tingling in hands	1	1
heart racing	1	1
bradycardia	1	1
lightheadedness	1	1
cough	1	0
nausea and vomiting	1	0

7/17


Figure 7

Figure 8



9/17

Figure 9



10/17

Figure 10




Figure 11

11/17




Figure 12

12/17




Figure 13




Figure 14

14/17







Figure 15

15/17



**Figure 16****Figure 17**

17/17

